Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on VIR. Vir Biotechnology, Inc.'s share was trading at $11.09 as of April 20th. VIR's trailing P/E was 5.92 according to Yahoo Finance. Is VIR a good stock to buy? Photo by National Cancer Institute on Unsplash Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. VIR is repositioning its business around Chronic Hepatitis Delta (HDV) and its masked T cell engager oncology platform, with HDV emerging as the primary value driver. Its lead program combines tobevibart, a neutralizing monoclonal antibody, with elebsiran, an siRNA partnered with Alnylam Pharmaceuticals. Read More: 15 AI Stocks That Are Quietly Making Investors Rich Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Phase 2 SOLSTICE data showed a 77% Target Not Detected (TND) rate at
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsBusiness Wire
- Can Vir Biotechnology (VIR)'s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? [Yahoo! Finance]Yahoo! Finance
- Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 2/23/26 - Beat
VIR
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- VIR's page on the SEC website